Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
- Experimental gene therapy treatment used to try to stop most common cause of blindness in aging people on February 18, 2019 at 10:38 pm
(Gray News) – For the first time, a woman with the most common cause of blindness – age-related macular degeneration – has been treated with an experimental gene therapy in the hopes it will halt the ... […]
- What is wet macular degeneration on February 18, 2019 at 12:53 pm
Millions of people deal with age-related macular degeneration as they get older, but many don’t understand the difference between types of the condition or what they can do to lessen the effects. Dr S... […]
- Juvenile Macular Degeneration Treatment Market Research, Application and Global Industry Future Analysis 2025 on February 18, 2019 at 4:13 am
Global Juvenile Macular Degeneration Treatment Market latest research report offers a complete analysis of the industry influencing driving factors, impacting trends and demand , competitive landscape ... […]
- Macular Degeneration on February 17, 2019 at 1:50 pm
Age-related macular degeneration (AMD) is a chronic disease of the macula, the central area of the retina, and is the leading cause of irreversible vision loss in the developed world. AMD is classifie... […]
- Protect Your Aging Eyes From Macular Degeneration on February 15, 2019 at 2:00 pm
FRIDAY, Feb. 15, 2019 (HealthDay News) -- Age-related macular degeneration (AMD) is an incurable eye disease that affects millions of older Americans, but there are a number of things you can do to re... […]
- What you need to know about wet macular degeneration on February 14, 2019 at 6:35 am
Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or what they can do to lessen the effects. […]
- Top 7 Healthy Habits to Help Prevent Macular Degeneration on February 12, 2019 at 8:17 pm
Doctors aren't sure what causes age-related macular degeneration, a disease that affects millions of people in the United States. Also called AMD, it is known for causing blurred central vision due to ... […]
- What you need to know about Age-related Macular Degeneration. on February 12, 2019 at 4:01 am
(BPT) - The ability to see the people, places and things in front of you is one of life’s most precious gifts. Imagine a life without the ability to see these things clearly — what steps would you the... […]
- Researchers home in on genes linked to age-related macular degeneration on February 11, 2019 at 4:47 pm
Scientists have zeroed in on genes associated with age-related macular degeneration (AMD), a leading cause of vision loss and blindness among people age 65 and older. These findings provide a more exp... […]
- NIH researchers home in on genes linked to age-related macular degeneration on February 11, 2019 at 8:27 am
National Eye Institute scientists led a collaborative study and zeroed in on genes associated with age-related macular degeneration (AMD), a leading cause of vision loss and blindness among people age ... […]
via Google News and Bing News